Autres langues Inovio Pharmaceuticals, Inc.

Actions

INO

US45773H4092

Temps réel estimé Cboe BZX Autres places de cotation 20:48:35 29/04/2024			Varia. 5j.	Varia. 1 janv.
11,85 ^USD	+12,11 %		+19,06 %	+94,93 %

06/03	Transcript : Inovio Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 06, 2024
06/03	Inovio Pharmaceuticals, Inc. publie ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024	14:01
INOVIO to Participate in Upcoming Investor Conferences in May	14:01
Powell Comments, Middle East Tensions in Focus as US Equity Futures Gain Pre-Bell	16/04
Inovio Pharmaceuticals Shares Slump Pre-Bell After Pricing of $36 Million Offering of Common Stock, Warrants	16/04
Top Premarket Decliners	16/04
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	16/04
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine	26/03
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	07/03
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024	21/02
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02
INOVIO Reports Inducement Grant Under Inducement Plan	02/02
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split	23/01
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader	22/01
Inovio Pharmaceuticals, Coherus BioSciences to Collaborate on Potential Throat Cancer Treatment	04/01
INOVIO and Coherus Announces Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI?? (toripalimab-Ttzi)	04/01
Inovio Pharmaceuticals Plans BLA Submission for INO-3107 for Recurrent Respiratory Papillomatosis Treatment	03/01
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program	03/01
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program	03/01
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) dropped from NASDAQ Biotechnology Index	15/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Inovio Pharmaceuticals, Inc.

Actions

INO

US45773H4092

Autres langues

Filtres